Complete if Known Substitute for form 1449/PTO Application Number 10/544093 Filing Date August 1, 2005 INFORMATION DISCLOSURE First Named Inventor Yednock, Ted STATEMENT BY APPLICANT Art Unit 1649 (Use as many sheets as necessary) Examiner Name Emch, Gregory S. Attomey Docket Number 15270C-009820US 7 1 of Sheet

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1 1	Number Kind Code ^{2 (Finance)}			rigures Appear
	1169	2009/0142270 A1	06-04-2009	Schroeter et al.	
	1166	2009/0069544 A1	03-12-2009	Basi et al.	
	1103	2008/0145373	06-19-2008	Arumugham et al.	
	1153	2006/0234912	10-16-2006	Wang et al.	
	1154	2006/0182321	08-17-2006	Hu et al.	
	1155	2006/0121038	06-08-2006	Schenk et al.	
	1101	2003/0054484 A1	03-20-2003	Fong et al.	
	1170	2003/0009104 A1	01-09-2003	Hyman et al.	
	1116	6,057,098	05-02-2000	Buechler et al.	
	1131	6,015,662	01-18-2000	Hackett et al.	
	1148	5,773,007	06-30-1998	Penney et al.	
	1147	5,723,130	03-03-1998	Hancock et al.	
	1168	5,620,844	04-15-1997	Neurath et al.	
	1160	5,472,693	12-05-1995	Gourlie et al.	

			U.S. PATENT APP	LICATIONS	
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passeges or Relevant
Illioale	10.	Number Kind Code ^{2 (Khown)}			Figures Appear
	1129	11/842,085	08-20-2007	Schenk	

				FOREIGN F	PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY		or Relevant Figures Appear	Ľ
	1102	EP	1 690 547	A1	08-16-1998			L
	1135	WO	08/131298	A3	12-18-2008			
	1107	WO	08/131298	A2	10-30-2008			
	1133	WO	06/042158	Α	04-20-2006			
	1146	WO	05/035753	Α	04-21-2005			
	1152	WO	01/78777	A2	10-25-2001			I

Examiner Signature Date Considered		
	Date Considered	

EXAMINER initial if elerence considered, which or not clinten is in conformace, with MPCP 800. Deve line through clinton in not formace and not considered to considered t

Subs	titute for form 1449/PTO			Complete if Known		
0000	and to rom 11101 10			Application Number	10/544093	
				Filing Date	August 1, 2005	
INFORMATION DISCLOSURE				First Named Inventor	Yednock, Ted	
ST	FATEMENT BY AP	PLI	CANT	Art Unit	1649	
	(Use as many sheets as ne	cessar	y)	Examiner Name	Emch, Gregory S.	
Sheet	2	of	7	Attorney Docket Number	15270C-009820US	

				FOREIGN I	PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MINI-DD-1111		Or Neicvani, Figures / ippear	Ľ
	1173	wo	97/18855	A1	05-29-1997			L
	1151	WO	96/39834	A1	12-19-1996			
	1174	WO	90/14840	A1	12-13-1990			
	1145	wo	87/02671	Α	05-07-1987			

Examiner Signature	Date Considered	

EXAMPLET: Initial if indurence consistency dividing or not classified in in conformance, with MPEP 800. Draw line through classics in first in conformance with MPEP 800. Draw line through classics in first in conformance of the conformance o

Substitute	for form 1449/PTO			Complete if Known			
				Application Number	10/544093		
INFO	RMATION D	SCLOS	URE	Filing Date	August 1, 2005		
STATEMENT BY APPLICANT				First Named Inventor	Yednock, Ted		
				Art Unit	1649		
	(Use as many sheets a	s necessary)		Examiner Name	Emch, Gregory S.		
Sheet	3	of	7	Attorney Docket Number	15270C-009820US		

Fxaminer	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials *	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1120	ARMOUR et al., "Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activites," <u>J. Immunol</u> , 29:2613-2624 (1999).	
	1117	AVIS, "Parenteral Preparations," Remington's Pharmaceutical Sciences, 17:1518-1519 (1985).	
	1138	BRINKMAN, "Splice Variants as Cancer Biomarkers," Clinical Biochemistry, 37(7):584-594 (2004).	
	1110	CHEN et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," <u>J. Mol. Biol.</u> , 293:865-881 (1999).	
	1142	CHOI et al., "A Generic Intron Increases Gene Expression in Transgenic Mice," Molecular and Cellular Biology, 11(6):3070-3074 (1991).	
	1132	CORCORAN et al., "Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease," Learn Mem. 9(5):243-252:2000.	С
	1144	DATABASE Geneseq, "Nucleotide Sequence of a Variable Heavy Chain of IgG4," EBI Accession No. GSN:ADZ51216 (2005).	
	1137	Extended European Search Report of 12/18/08 for European Application 05812436.6-1212.	
	1136	European Examination Report of 09/23/2008 for European Application 04776252.1-2405.	
	1130	European Examination Report as part of 12-08-2008 communication for European Application 04720353.4	С

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicants unique citation designation number (optional)**, "Applicants into pictors exhert where if English language Translation is attached.

Substitute	for form 1449/PTC	1		Complete if Known			
				Application Number	10/544093		
INFO	RMATION	I DISCLOS	URE	Filing Date	August 1, 2005		
STA	TEMENT E	BY APPLIC	ANT	First Named Inventor	Yednock, Ted		
				Art Unit	1649		
	(Use as many she	eets as necessary)		Examiner Name	Emch, Gregory S.		
Sheet	4	of	7	Attorney Docket Number	15270C-009820US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journals, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1134	European Examination Report of 11/20/2008 for European Application 08011409.3	
	1150	Family and legal status of EP0613007, Inpadoc Search (2009).	
	1163	Genbank Accession number AAA69734, Schroeder et al., "Immunoglobulin heavy chain [Homo sapiens]", Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 07/11/95.	
	1164	Genbank Accession number BAC01733, Akahori et al., "Immunoglobulin kappa light chain VI.J region [Homo sapiens]", 07/02/02.	
	1118	HEZAREH et al., "Effecter Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>Journal of Virology</u> , 24(75):12161-12168 (2001).	
	1127	JANEWAY et al., Immunobiology, 3 rd edition, pages 8:18-8:19 (1997).	
	1121	MANN et al., "Atypical Amyloid (ABeta) Deposition in the cerebellum in Alzheimer's Disease: An Immunohistochemical Study Using End-Specific ABeta Monoclonal Antibodies," <u>ACTA Neuropathologica</u> , 91:647-653 (1996).	
	1122	MANN et al., "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutatuibs in the amyloid precursor protein gene," The <u>American Journal of Pathology APR</u> , 4(148): 1257-1266 (1996).	
	1157	MAVRAGANI et al., "A Case of Reversible Posterior Leucoencephalopathy Syndrome After Rityximab Infusion," Rheumatology, 43(11) 1450-1451 (2006).	

-		 	
ı	Examiner	Date	
ı	Signature	Considered	

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with not communication to applicant.

"Applicants unjugic existion designation number (optional," Applicant is to place a check mark here if English language Translation is attached.

 						_	
Substitute	for form 1449/PTO			Complete if Known			
				Application Number	10/544093		
INFO	RMATION DI	SCLOS	URE	Filing Date	August 1, 2005	_	
STAT	EMENT BY A	APPLIC	ANT	First Named Inventor	Yednock, Ted		
				Art Unit	1649		
	(Use as many sheets as	necessary)		Examiner Name	Emch, Gregory S.	-	
 Sheet	5	of	7	Attorney Docket Number	15270C-009820US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1139	MYERS et. al., "Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 514-Specific SCFV Fusion Proteins," Cancer Gene Therapy, 9(11):884- 896 (2002).	
	1167	PADLAN et al., "Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL-10 Fab-lysozyme Complex, Immunology, 86:5938-5942 (1989).	
	1171	PANGALOS et al., "Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of β-amyloid Peptide," Biochemical Society Transactions, 33(4):553-558 (2005).	С
	1108	PASCALIS et al., "Grafting of "Abbreviated" Complementarity-Determining Containing Specifidty-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody, "The <u>Journal Immunology</u> , 169:3076-3084 (2002).	
	1158	PCT Written Opinion of 12/22/2008 for application PCT/US2008/80370.	
	1159	PCT Search Report of 01/22/2009 for application PCT/US2008/80370.	
	1172	PRADA et al., "Antibody-Mediated Clearance of Amyloid-β Peptide From Cerebral Amyloid Angiopathy Revealed by quantitative in Vivo Imaging," Journal of Neuroscience, 27(8):1973- 1980 (2007).	С
	1149	QU et al., "A β_Q gene Vaccine Prevents A β_Q deposition in brain of Double Trangenic Mice," <u>J. Neurological Sciences</u> , 260:204-213 (2007).	
	1141	ROBBINS et al., 'The Intronic Region of an Incompletely Spliced gp100 Gene Transcript Encodes an Epitope Recognized by Melanoma-Reactive Tumor-Inflitrating Lymphocytes," Journal of Immunology, 159(1):303-308 (1991).	

Examiner Signature	Date Considered	

EXAMINER; initial if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicants ruing outland neighbor number optional, "Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449/PTO				Complete if Known	
				Application Number	10/544093	
INFO	RMATION D	ISCLOS	URE	Filing Date	August 1, 2005	
STA	TEMENT BY	APPLIC	ANT	First Named Inventor	Yednock, Ted	
				Art Unit	1649	
	(Use as many sheets	as necessary)		Examiner Name	Emch, Gregory S.	
Sheet	6	of	7	Attorney Docket Number	15270C-009820US	

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1123	SCHMIDT et al., "Monoclonal Antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains," The American Journal of Pathology, 1(161):68-80 (1997).	Г
	1165	SCHROEDER et al., "Preferential Utilization of Conserved Immunoglobulin Heavy Chain Variable Gene Segments During Human Fetal Life," Immunology , 87:6146-6150 (1990).	
	1140	SEABROOK et al., "Species-specific Immune response to Immunization with Human Versus rodent Abeta Peptide," Neuobiology of Aging, 25(9) 1141-1151 (2004)	
	1119	Shepherd et al., "The design of the humanized antibody," Monocolonal Antibodies: A Practical Approach 58-66 (2000)	
	1104	SIDHU, "Page display in pharmaceutical biotechnology," <u>Current Opinion in Biotechnology</u> . 11:610-616 (2000).	
	1105	SMITH et al., "Phage Display," Chemical Reviews, American Chemical Society, 97(2):391-410 (1997).	
	1128	STUDNICKA et al., "Human-engineered monocilnal antibodies retain full specific binding activity by preserving non-CDR complemenatary-modullating resudes," Protein Eng., 7(8):805-814 (1994), Abstract only.	
	1124	TAMAOKAet al., "Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehyrogenase (GAPDH)," Neurobiology of Aging, 3(17):405-414 (1996).	
	1162	TRANG et al., "Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1A) in Metastatic Adencarcinoma Patients," Pharmacutical Research 7(6):587-592 (1990).	
	1112	U.S. Application No. 09/316,387, Office Action mailed 09/10/2007.	
	1113	U.S. Application No. 09/316,387, Response to 06-20-2005 Office Action filed 12-20-2005.	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant is unique citation designation number (potional). *Applicant is unique citation designation.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/544093	
INFO	RMATION	DISCLOS	SURE	Filing Date	August 1, 2005	
	TEMENT E			First Named Inventor	Yednock, Ted	
•				Art Unit	1649	
	(Use as many she	ets as necessary)		Examiner Name	Emch, Gregory S.	
Sheet	7	of	7	Attorney Docket Number	15270C-009820US	

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1114	U.S. Application No. 09/316,387, Declaration of Solomon, Hrncic, and Wall under 37 C.F.R. § 1.131 filed 03-06-2008.	
	1115	U.S. Application No. 09/316,387, Office Action mailed 06/20/2005.	Е
	1109	VAJDOS et al., "Comprehensive Functional Maps of the Antigen-binging site of an Anti, ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," <u>J. Mol. Biol.</u> , 320:415-428 (2002).	С
	1143	WARD et al., "Spontaneous Deletions In IG Heavy Chain Genes Flaking Sequences Influence Splice Site Selection Nucleic Acids Research," 19(23): 6475-6480 (1991).	
	1161	Wikipedia entry for Antibody, retrieved April 27, 2009 from http://en.wikipedia.org/wiki/Antibody.	
	1106	WILSON et al., "Phage display: applications, innovations, and issues in phage and host biology," Can. J. Microbiol. 44:313-329 (1998).	
	1111	WU et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," <u>J. Mol. Biol.</u> , 294:151-162 (1999).	
	1125	YANAGISAWA K et al., "Amyloid BETA-protein (Alpha-Beta) associated with lipid molecules: immunoreactivity distinct from that of soluble Alpha-Beta," FEBS Letters, 1(420): 43-46 (1997).	
	1126	YANG et al., "Monoclonal Antibody to the C-terminus of Beta-Amyloid," Neuroreport, 16(5):2117-2120 (1994).	

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with ext communication to applicant.

Applicants unique citation designation number (optional). Applicants is top lace a check mark here if English language Translation is attached.